Paralysis: Clinical Trials

28 trials for Paralysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed. 28 Phase 3, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 328Completed 28
Phase 210Completed 10

Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops - Blepharoptosis, Synkinesis
Phase 3CompletedMilton S. Hershey Medical Center362024-01-112026-03-09
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Tradipitant - Idiopathic Gastroparesis, Diabetic Gastroparesis
Phase 3CompletedVanda Pharmaceuticals172024-01-092026-10-19
AMX0035 and Progressive Supranuclear Palsy
AMX0035, Placebo - Progressive Supranuclear Palsy, PSP
Phase 2 / Phase 3CompletedAmylyx Pharmaceuticals Inc.1392023-12-212026-04-30
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Elamipretide, Placebo - Mitochondrial Myopathies, Mitochondrial Pathology
Phase 3CompletedStealth BioTherapeutics Inc.1022022-04-292025-10-24
PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle - Diabetes, Gastroparesis With Diabetes Mellitus
Phase 2 / Phase 3CompletedMayo Clinic122021-05-102023-04-18
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD)
Phase 3CompletedGE Healthcare1722020-06-282023-10-16
Diaphragmatic Paralysis Comparison Between Local Anesthetic Volumen Doses After Interscalene Block
Interscalene brachial plexus block, Levobupivacaine Hydrochloride 2.5 MG/ML - Diaphragmatic Paralysis, Brachial Plexus Block
Phase 3CompletedInstituto de Investigación Sanitaria Aragón482020-02-112022-08-12
Interscalene Block and Dysfunction Diaphragmatic
Ropivacaine 0.5% Injectable Solution, Ropivacaine 0.1% Injectable Solution - Diaphragmatic Paralysis
Phase 3CompletedUniversity Hospital, Lille602019-10-292026-06-11
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Tradipitant, Placebo, Open Label Tradipitant - Idiopathic Gastroparesis, Diabetic Gastroparesis
Phase 3CompletedVanda Pharmaceuticals9792019-08-202026-09-24
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg - Dementia-related Psychosis
Phase 3CompletedACADIA Pharmaceuticals Inc.3922017-09-272021-06-21
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Rivastigmine, Placebo - Progressive Supranuclear Palsy (PSP)
Phase 3CompletedAssistance Publique Hopitaux De Marseille1062016-07-262023-07-20
Burke-Hocoma Efficiency Study
Hocoma ArmeoSpring - Hemiparesis, Hemiplegia
Phase 3CompletedBurke Medical Research Institute472016-05-012022-10-04
Fenofibrate Treatment in SCI
Fenofibrate, No intervention - Spinal Cord Injury, Dyslipidemia
Phase 2 / Phase 3CompletedVA Office of Research and Development232015-05-182019-06-26
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis
Metoclopramide Nasal Spray, Placebo Nasal Spray - Diabetic Gastroparesis
Phase 3CompletedEvoke Pharma532014-04-012020-07-07
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
Metoclopramide Nasal Spray, Placebo Nasal Spray - Diabetic Gastroparesis
Phase 3CompletedEvoke Pharma2052014-03-272020-07-07
Prucalopride Versus Placebo in Gastroparesis
Prucalopride, Placebo - Gastroparesis, Diabetes Mellitus
Phase 2 / Phase 3CompletedUniversity of Calgary152014-03-012020-10-08
Static and Dynamic Postural Stability in Cerebral Palsy Children
no distractor control group, visual and sound attentional distractors, sound attentional distractor alone - CP (Cerebral Palsy), Diplegia
Phase 3CompletedUniversity Hospital, Grenoble242013-02-012016-03-23
Sancuso® for Gastroparesis: An Open Label Study.
Sancuso® - Gastroparesis
Phase 3CompletedTemple University142012-11-012021-05-26
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Davunetide, Placebo - Progressive Supranuclear Palsy
Phase 2 / Phase 3CompletedAllon Therapeutics3132010-10-012013-01-17
MEOPA to Improve Physical Therapy Results After Multilevel Surgery
MEOPA, Medicinal air - Cerebral Palsy, Spastic Diplegia
Phase 3CompletedAssistance Publique - Hôpitaux de Paris642008-03-012023-02-03

Showing 20 of 28. Sign in to see all of them.

Narrower conditions

Gastroparesis (8)  ·  Supranuclear Palsy, Progressive (6)  ·  Nausea (5)  ·  Quadriplegia (5)  ·  Spinal Cord Injuries (5)  ·  Vomiting (5)  ·  Diabetes Mellitus (4)  ·  Hemiplegia (4)  ·  Abdominal Pain (2)  ·  Cerebral Palsy (2)  ·  Facial Paralysis (2)  ·  Respiratory Paralysis (2)  ·  Stomach Diseases (2)  ·  Alzheimer Disease (1)  ·  Asthma (1)

Broader conditions

Neurologic Manifestations (28)  ·  Pathological Conditions, Signs and Symptoms (28)  ·  Signs and Symptoms (28)  ·  Nervous System Diseases (19)  ·  Central Nervous System Diseases (14)  ·  Brain Diseases (9)  ·  Cranial Nerve Diseases (8)  ·  Digestive System Diseases (8)  ·  Eye Diseases (8)  ·  Gastrointestinal Diseases (8)  ·  Ocular Motility Disorders (7)  ·  Ophthalmoplegia (7)  ·  Basal Ganglia Diseases (6)  ·  Metabolic Diseases (6)

Interventions

NG-Nitroarginine Methyl Ester (2)  ·  Electric Stimulation Therapy (1)  ·  Fenofibrate (1)  ·  Granisetron (1)  ·  Injections (1)  ·  Iodine-123 (1)  ·  Levobupivacaine (1)  ·  Meopa (1)  ·  Methylprednisolone (1)  ·  Oxymetazoline (1)  ·  Rivastigmine (1)  ·  Ropivacaine (1)  ·  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1)  ·  coenzyme Q10 (1)  ·  davunetide (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (2)  ·  Evoke Pharma (2)  ·  US Department of Veterans Affairs (2)  ·  VA Office of Research and Development (2)  ·  Vanda Pharmaceuticals (2)  ·  ACADIA Pharmaceuticals Inc. (1)  ·  Allon Therapeutics (1)  ·  Amylyx Pharmaceuticals Inc. (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Burke Medical Research Institute (1)  ·  GE Healthcare (1)  ·  Instituto de Investigación Sanitaria Aragón (1)  ·  Lahey Clinic (1)  ·  Mayo Clinic (1)  ·  Milton S. Hershey Medical Center (1)

Countries

United States (18)  ·  France (8)  ·  Germany (5)  ·  Spain (4)  ·  Canada (3)  ·  Italy (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Chile (1)  ·  China (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Netherlands (1)

Top investigators

Adam Boxer, M.D., PhD. (1)  ·  Arthur Prochazka (1)  ·  Charles Burgar, MD (1)  ·  Christopher N Andrews, MD, MSc (1)  ·  Diana Apetauerova, MD (1)  ·  Henry P Parkman, MD (1)

Results publications

PMID 17385265, PMID 17965289, PMID 19618698, PMID 19651280, PMID 20012982, PMID 21372246, PMID 21674393, PMID 21762873, PMID 21872708, PMID 23700789, PMID 24873720, PMID 28436538, PMID 28726270, PMID 32250331, PMID 33874993, PMID 34289275, PMID 34934801, PMID 37924856, PMID 38237696, PMID 38825840, PMID 41286676, PMID 42244823

NIH funding

2016 (1), 2017 (1), 2019 (1)